Baseline Quantitative Hepatitis B Core Antibody Titer Alone Strongly Predicts HBeAg Seroconversion a

来源 :2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议 | 被引量 : 0次 | 上传用户:szzc2001
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background:The investigation regarding the clinical significance of quantitative hepatitis B core antibody(anti-HBc) during chronic hepatitis B(CHB) treatment is few.
其他文献
1.Ontogenetic differences have genetic background?There may be individual genetic background whether hepatitis B aggravate.
会议
Hepatic steatosis is a common feature in patients with chronic hepatitis C virus(HCV) infection.HCV core protein plays an important role in the development of hepatic steatosis in HCV infection.
会议
Chronic infection with hepatitis B virus(HBV) contributes to more than three quarters of hepatocellular carcinoma(HCC) cases worldwide.It remains a great challenge to know how HBV causes HCC.
会议
Background:Chronic hepatitis B virus(HBV) infection and subsequent chronic inflammation are major risk factors of hepatocellular carcinoma(HCC) in China.
会议
Interferon-alfa(IFN-α) has dual mode of actions of inhibiting hepatitis B virus(HBV) DNA replication and modulating the host immune response against HBV.1 Pegylated formation of interferon-alfa(pegint
会议
Aims:To investigate the prevalence of HBV in HIV-infected adults in Guangdong province and assess the frequency of lamivudine(3TC) resistance mutations in HIV/HBV co-infected patients treated with 3TC
会议
Background:Chronic hepatitis B virus(HBV) infection and subsequent chronic inflammation are major risk factors of hepatocellular carcinoma(HCC) in China.
会议
Background:Natural killer(NK) cells have been implicated in inducing fibrosis remission in mice model;however,their roles in fibrotic progression remain to be elucidated in patients with liver fibrosi
会议
Background:T-helper(Th) 22 cells and IL-22 are linked to the development of inflammatory and autoimmune disease.Acute-on-chronic liver failure(ACLF) is an increasingly recognised entity encompassing a
会议
Background:Current therapies for chronic hepatitis B(CHB) afford durable post-treatment responses in a minority of patients.
会议